Lipocine Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LPCN$1.72+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
For the Years Ended December 31, 2023 and 2022
| Mezzanine Equity · Stockholder’s Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred Stock · Common Stock · Treasury Stock · Additional · Accumulated Other · Total | |||||||||||
| Number of Shares · Amount · Number of Shares · Amount · Number of Shares · Amount · Paid-In Capital · Comprehensive Loss · Accumulated Deficit · Stockholders’ Equity | |||||||||||
| Balances at December 31, 2021 | - | $ | - | 5,221,883 | $8,830 | 336 | $(40,712) | $218,286,323 | $(18,016) | $(172,666,407) | $45,570,018 |
| Net loss | - | - | - | - | - | - | - | - | (10,758,636) | (10,758,636) | |
| - | |||||||||||
| Unrealized net loss on marketable investment - securities | - | - | - | - | - | - | - | (2,305) | - | (2,305) | |
| - | |||||||||||
| Stock-based compensation | - | - | - | - | - | - | 636,140 | - | - | 636,140 | |
| - | |||||||||||
| Option exercises | - | - | 12,947 | 22 | - | - | 211,401 | - | - | 211,423 | |
| - | |||||||||||
| Costs associated with ATM Offering | - | - | - | - | - | - | (21,700) | - | - | (21,700) | |
| Balances at December 31, 2022 | - | $ | - | 5,234,830 | $8,852 | 336 | $(40,712) | $219,112,164 | $(20,321) | $(183,425,043) | $35,634,940 |
| Mezzanine Equity · Stockholder’s Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred Stock · Common Stock · Treasury Stock · Additional · Accumulated Other · Total | |||||||||||
| Number of Shares · Amount · Number of Shares · Amount · Number of Shares · Amount · Paid-In Capital · Comprehensive Loss · Accumulated Deficit · Stockholders’ Equity | |||||||||||
| Balances at December 31, 2022 | - | $ | - | 5,234,830 | $8,852 | 336 | $(40,712) | $219,112,164 | $(20,321) | $(183,425,043) | $35,634,940 |
| Net loss | - | - | - | - | - | - | - | - | (16,352,082) | (16,352,082) | |
| Unrealized net gain on marketable investment securities | - | - | - | - | - | - | - | 27,580 | - | 27,580 | |
| Stock-based compensation | - | - | - | - | - | - | 654,438 | - | - | 654,438 | |
| Issuance of Series B preferred stock dividend | 88,511 | 9 | - | - | - | - | 80 | - | 80 | ||
| Redemption of Series B preferred stock | (88,511) | (9) | - | - | - | - | 9 | - | (89) | (80) | |
| Common stock sold through ATM offering | - | - | 81,000 | 8 | - | - | 404,559 | - | - | 404,567 | |
| Balances at December 31, 2023 | - | $ | - | 5,315,830 | $8,860 | 336 | $(40,712) | $220,171,250 | $7,259 | $(199,777,214) | $20,369,443 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.